Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 3/20 | 1.00 |
| ▸ | CDC25B | P30305 | 2/20 | 0.63 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.58 |
| ▸ | CES2 | O00748 | 7/20 | 0.51 |
| ▸ | CES1 | P23141 | 7/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | CDC25A | P30304 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.42 |
| ▸ | GAPDH | P04406 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8473068 | 0.87 | PTPRC (0.77) | PTPRCCDC25BPTPN1CES2CES1 | |
| SCHEMBL29771457 | 0.87 | PTPRC (0.77) | PTPRCCDC25BPTPN1CES2CES1 | |
| SCHEMBL14439359 | 0.81 | PTPRC (0.68) | PTPRCCDC25BPTPN1CES2CES1 | |
| SCHEMBL5595688 | 0.81 | PTPRC (0.68) | PTPRCCDC25BPTPN1CES2CES1 | |
| SCHEMBL6052754 | 0.80 | PTPRC (0.67) | PTPRCCDC25BPTPN1CES2CES1 | |
| SCHEMBL14439360 | 0.80 | PTPRC (0.67) | PTPRCCDC25BPTPN1CES2CES1 | |
| SCHEMBL21870558 | 0.78 | PTPRC (0.63) | PTPRCCDC25BCES2CES1ALDH1A1 | |
| SCHEMBL5595641 | 0.77 | PTPRC (1.00) | PTPRCCDC25BPTPN1CES2CES1 | |
| SCHEMBL23573639 | 0.75 | PTPRC (0.60) | PTPRCALDH1A1CYP3A4MAPTHPGD | |
| SCHEMBL14439325 | 0.75 | PTPRC (0.65) | PTPRCCDC25BPTPN1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939896-B2 | Naphthalenedione derivatives; treating autoimmune diseases and organ graft rejection | ASTRAZENECA AB (SE) | 2005-09-06 | — | — | US | disclosed |
| EP-1259231-B1 | NAPHTHOQUINONE DERIVATIVES AS CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2005-05-25 | — | — | EP | disclosed |
| US-20030119897-A1 | Cd45 inhibitors | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | US | disclosed |
| EP-1259231-A2 | NAPHTHOQUINONE DERIVATIVES AS CD45 INHIBITORS | AstraZeneca AB (SE) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001045681-A2 | NAPHTHOQUINONE DERIVATIVES AS CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119897-A1 | Cd45 inhibitors | PTPRC, CD2, HLA-C | PTPRC 1/4885CDC25B 187/4885PTPN1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.